Cost-effectiveness of drug therapies for Alzheimer’s disease: A brief review

References

• [AD2000] AD2000 Collaborative GroupLong-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): Randomised double-blind trialLancet200436321051515220031
   PubMed Web of Science ®Google Scholar
• AevarssonOSkoogIA population-based study on the incidence of dementia disorders between 85 and 88 years of ageJ Am Geriatr Soc1996441455608951315
   PubMed Web of Science ®Google Scholar
• BirksJCholinesterase inhibitors for Alzheimer’s diseaseCochrane Database Syst Rev20061CD00559316437532
   PubMed Web of Science ®Google Scholar
• CallahanCMHendrieHCTierneyWMDocumentation and evaluation of cognitive impairment in elderly primary care patientsAnn Intern Med199512242297856990
   PubMed Web of Science ®Google Scholar
• ClarkeNAD2000 design and conclusions [Letter]Lancet200436412151615464176
   PubMed Web of Science ®Google Scholar
• CummingsJLSchneiderETariotPNBehavioral effects of memantine in Alzheimer disease patients receiving donepezil treatmentNeurology200667576316832078
   PubMed Web of Science ®Google Scholar
• EvansDAFunkensteinHHAlbertMSPrevalence of Alzheimer’s disease in a community population of older persons. Higher than previously reportedJAMA1989262255162810583
   PubMed Web of Science ®Google Scholar
• FeldmanHGauthierSHeckerJEconomic evaluation of donepezil in moderate to severe Alzheimer diseaseNeurology2004636445015326236
   PubMed Web of Science ®Google Scholar
• FerriCPrinceMBrayneCGlobal prevalence of dementia: a Delphi consensus studyLancet200536621121716360788
   PubMed Web of Science ®Google Scholar
• FillitHGuttermanEMLewisBDonepezil use in managed Medicare: Effect on health care costs and utilizationClin Ther19992121738510645761
   PubMed Web of Science ®Google Scholar
• FillitHHillJWFuttermanRHealth care utilization and costs of Alzheimer’s disease: The role of co-morbid conditions, disease stage, and pharmacotherapyFam Med2002345283512144008
   PubMed Web of Science ®Google Scholar
• GuttermanEMarkowitzJLewisBCost of Alzheimer’s disease and related dementia in managed-MedicareJ Am Geriatr Soc19994710657110484247
   PubMed Web of Science ®Google Scholar
• GreenCPicotJLovemanEModelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer’s diseasePharmacoeconomics20052312718216336020
   PubMed Web of Science ®Google Scholar
• HauberABGnanasakthyASnyderEHPotential savings in the cost of caring for Alzheimer’s disease: Treatment with rivastigminePharmacoeconomics2000173516010947490
   PubMed Web of Science ®Google Scholar
• HerrmannNLanctotKLSambrookRThe contribution of neuropsychiatric symptoms to the cost of dementia careInt J Geriatr Psychiatry200621972616955429
   PubMed Web of Science ®Google Scholar
• HillJWFuttermanRDuttaguptaSAlzheimer’s disease and related dementias increase costs of comorbidities in managed MedicareNeurology200258627011781407
   PubMed Web of Science ®Google Scholar
• HillJWFuttermanRMasteyVThe effect of donepezil therapy on health costs in a Medicare managed care planManag Care Interface200215637011925682
   PubMedGoogle Scholar
• JonesRWMcCronePGuilhaumeCCost effectiveness of memantine in Alzheimer’s disease. An analysis based on a probabilistic Markov model from a UK perspectiveDrugs Aging2004216072015260515
   PubMed Web of Science ®Google Scholar
• KoppelRAlzheimer’s Disease: The Costs to U.S. Businesses in 2002 [online]2002Chicago, ILAlzheimer’s Association Accessed December 1, 2006 URL: http://www.alz.org/Downloads/062602ADCosts.pdf
   Google Scholar
• LangaKMChernewMEKabetoMUNational estimates of the quantity and cost of informal caregiving for the elderly with dementiaJ Gen Intern Med200116770811722692
   PubMed Web of Science ®Google Scholar
• LuSHillJFillitHImpact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer’s disease and related dementias enrolled in a large Medicare managed care plan: A case-control studyAm J Geriatr Pharmacother200539210216129386
   PubMedGoogle Scholar
• MohsRCDoodyRSMorrisJCA 1-year, placebo-controlled preservation of function survival study of donepezil in AD patientsNeurology200157481811502917
   PubMed Web of Science ®Google Scholar
• NaglieGTomlinsonGTamseyCUtility-based quality of life measures in Alzheimer’s diseaseJ Quality Life20061563143
   PubMed Web of Science ®Google Scholar
• NeumannPJGoldieSJWeinsteinMCPreference based measures in economic evaluation in health careAnn Rev Public Health20002158761110884966
   PubMed Web of Science ®Google Scholar
• NeumannPJHealth utilities in Alzheimer’s disease and implications for cost-effectiveness analysisPharmacoeconomics200523437541
   Web of Science ®Google Scholar
• PloskerGLLyseng-WilliamsonKAMemantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer’s diseasePharmacoeconomics20052319320615748093
   PubMed Web of Science ®Google Scholar
• RockwoodKGrahamJEFaySGoal setting and attainment in Alzheimer’s disease patients treated with donepezilJ Neurol Neurosurg Psychiatry200273500712397141
   PubMed Web of Science ®Google Scholar
• RockwoodKBlackSERobillardAPotential treatment effects of donepezil not detected in Alzheimer’s disease clinical trials: a physician surveyInt J Geriatr Psychiatry2004199546015449367
   PubMed Web of Science ®Google Scholar
• SiegelJETorranceGWRussellLBGuidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost effectiveness in Health and MedicinePharmacoeconomics1997111596810172935
   PubMed Web of Science ®Google Scholar
• SmallGWDonahueJABrooksRLAn economic evaluation of donepezil in the treatment of Alzheimer’s diseaseClin Ther199820838509737841
   PubMed Web of Science ®Google Scholar
• SmallGWMcDonnellDDBrooksRLThe impact of symptom severity on the cost of Alzheimer’s diseaseJ Am Geriatr Soc200250321712028215
   PubMed Web of Science ®Google Scholar
• StewartAPhillipsRDempseyGPharmacotherapy for people with Alzheimer’s disease: A Markov-cycle evaluation of five years therapy using donepezilInt J Geriatric Psychiatry19981344553
   PubMed Web of Science ®Google Scholar
• TrinhNHHoblynJMohantySEfficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysisJAMA20032892101612517232
   PubMed Web of Science ®Google Scholar
• WardACaroJJGetsiosDAssessment of health economics in Alzheimer’s disease (AHEAD): treatment with galantamine in the UKInt J Geriatric Psychiatry2003187407
   PubMed Web of Science ®Google Scholar
• WimoAWinbladBEngedalKAn economic evaluation of donepezil in mild to moderate Alzheimer’s disease: Results of a 1-year double-blind randomized trialDement Geriatr Cogn Disord2003a15445412457078
   PubMed Web of Science ®Google Scholar
• WimoAWinbladBStofflerAResource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer’s diseasePharmacoeconomics2003b213274012627986
   PubMed Web of Science ®Google Scholar
• WimoACost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer’s disease: a review with methodological considerationsDrugs Aging2004212799515040756
   PubMed Web of Science ®Google Scholar
• WimoAWinbladBJönssonLAn estimate of the total worldwide societal costs of dementia in 2005Alzheimer Dement200738191
   PubMed Web of Science ®Google Scholar
• WolstenholmeJFennPGrayAEstimating the relationship between disease progression and cost of care in dementiaBr J Psychiatry2002181364212091261
   PubMed Web of Science ®Google Scholar
• ZhuCWScarmeasNTorganRLongitudinal study of effects of patient characteristics on direct costs in Alzheimer diseaseNeurology2006619971005
   Google Scholar